Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Sold by Tiff Advisory Services LLC

Tiff Advisory Services LLC trimmed its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 10.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,032,752 shares of the company's stock after selling 115,000 shares during the quarter. Roivant Sciences makes up about 3.7% of Tiff Advisory Services LLC's holdings, making the stock its 10th biggest position. Tiff Advisory Services LLC owned 0.14% of Roivant Sciences worth $10,916,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of ROIV. nVerses Capital LLC acquired a new stake in Roivant Sciences during the 2nd quarter worth approximately $34,000. Acadian Asset Management LLC purchased a new position in Roivant Sciences in the 1st quarter valued at $72,000. Fifth Third Wealth Advisors LLC acquired a new position in Roivant Sciences in the 2nd quarter valued at $101,000. ORG Partners LLC purchased a new position in Roivant Sciences during the 2nd quarter worth $106,000. Finally, Premier Path Wealth Partners LLC acquired a new stake in shares of Roivant Sciences in the 1st quarter worth $126,000. Hedge funds and other institutional investors own 64.76% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on ROIV shares. Cantor Fitzgerald reissued an "overweight" rating on shares of Roivant Sciences in a report on Monday. HC Wainwright reissued a "buy" rating and set a $18.00 target price on shares of Roivant Sciences in a research note on Monday, August 19th. Finally, Piper Sandler raised their price target on Roivant Sciences from $20.00 to $22.00 and gave the company an "overweight" rating in a report on Wednesday, July 10th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $17.10.

Roivant Sciences Price Performance

Roivant Sciences stock traded up $0.20 during trading hours on Monday, hitting $12.50. The stock had a trading volume of 15,803,926 shares, compared to its average volume of 5,702,539. Roivant Sciences Ltd. has a 1-year low of $8.24 and a 1-year high of $13.24. The stock has a market capitalization of $9.24 billion, a price-to-earnings ratio of 2.47 and a beta of 1.25. The stock's fifty day moving average is $11.24 and its two-hundred day moving average is $11.02. The company has a debt-to-equity ratio of 0.05, a current ratio of 27.91 and a quick ratio of 27.91.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.33. Roivant Sciences had a net margin of 2,991.75% and a negative return on equity of 17.23%. The firm had revenue of $55.10 million during the quarter, compared to the consensus estimate of $30.72 million. During the same period last year, the firm posted ($0.38) EPS. The firm's revenue for the quarter was up 155.1% on a year-over-year basis. As a group, analysts predict that Roivant Sciences Ltd. will post -1.14 earnings per share for the current fiscal year.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.